Want to see AU:TRP full AI Analyst Report?
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$6.65M
Enterprise Value-AU$1.95M
Total Cash (Recent Filing)AU$8.29M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsThe sharp revenue acceleration coupled with very high gross margins indicates meaningful product-market traction and strong unit economics. If management sustains sales growth while leveraging fixed R&D and G&A, revenue mix and margin dynamics can support durable progress toward breakeven over the next several quarters.
Debt-Free Balance SheetA consistently debt-free capital structure materially lowers financial risk and interest burden. This structural strength increases flexibility for equity financings, partnerships, or milestone-driven investments without fixed repayment pressure, improving resilience during funding cycles and industry volatility.
Lean Headcount / Operational LeverageA very small employee base suggests low fixed operating overhead and potential operational leverage as revenue scales. With tight staff, incremental revenue can flow to margins faster than for labor-intensive peers, helping extend runway and enabling the company to prioritize capital allocation toward high-return R&D or commercialization.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flows point to structural cash burn that will require recurring financings unless margins improve. Rising cash outflows erode runway, elevate dilution risk and limit ability to fund development or commercialization initiatives without external capital over the medium term.
Deep & Persistent Net LossesVery large negative margins reflect heavy investment and limited earnings visibility. Persistent losses hinder cash generation and return metrics, constrain strategic options, and mean that operational improvements must be sustained to convert recent revenue gains into profitable growth over the coming quarters.
Material Equity ErosionSignificant decline in shareholders' equity reduces the balance-sheet cushion against further losses and increases reliance on external funding. Lower equity limits borrowing capacity, magnifies dilution implications of future raises, and reflects cumulative operating losses that weaken long-term financial flexibility.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.10 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$6.65M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 29 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.036.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.56%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Technical Analysis
Acrux
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―